Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study

Publication | Open Access

DOI Full Paper Access

Citations

References

2022

Year

Zhigang Liu, Kaixing Le, Xin Zhou, James L. Alexander, Simeng Lin, Claire Bewshea, Neil Chanchlani, Rachel Nice, Timothy J. McDonald, Christopher A Lamb,

The Lancet. Gastroenterology & hepatology